GHRP-2 Reconstitution Calculator

GHRP-2 (pharmaceutical name pralmorelin) is a synthetic hexapeptide growth hormone secretagogue that activates the ghrelin receptor (GHS-R1a) in the pituitary, prompting it to release pulses of your own growth hormone. It's one of the most potent GH-releasing peptides — stronger than GHRP-6 for raw GH output — and unlike injected HGH it works through your existing GH axis rather than supplying the hormone directly. It is a research peptide, not an approved therapeutic drug in the US.

In research literature GHRP-2 is dosed in micrograms — commonly around 100–200 mcg per injection, subcutaneously, two to three times a day. Its half-life is short (roughly 30 minutes to a couple of hours), so doses are usually spaced through the day and often timed to an empty stomach, since food (especially fats) can blunt the GH pulse. These are commonly cited research figures, not an approved regimen — dose, frequency, and suitability are clinical decisions.

Add bacteriostatic water to the dry vial slowly and swirl gently — never shake. For example, a 5 mg vial + 2.5 mL of water gives 2 mg/mL (2,000 mcg/mL); a 200 mcg dose is then 0.1 mL, which is 10 units on a U-100 insulin syringe. Use the calculator above to match your vial's real strength (5 mg and 10 mg are common) and your target dose. Doses here are in micrograms, so small volume errors matter more than with milligram-scale peptides.

GHRP-2 sits in the middle of the GHRP selectivity spectrum: it does stimulate appetite, but moderately — more than ipamorelin (which barely touches hunger) and less than GHRP-6 (whose hunger spike is its signature). It also raises cortisol and prolactin modestly, again landing between those two. People typically choose GHRP-2 when they want stronger GH release than ipamorelin gives without GHRP-6's aggressive appetite — that trade-off, not a single "best" answer, is the entire point of choosing between them.

Despite forum worries that GHRP-2 might "shorten lifespan," there is no human evidence of that — the documented picture is different: its short-term human data is actually the strongest of any GHRP, yet no multi-year adult safety data exists, and any sustained GH/IGF-1 rise carries theoretical glucose and cancer-risk considerations. Reported effects include injection-site reactions, headache, transient cortisol elevation, and mild water retention. Notably, GHRP-2 (as pralmorelin) is the only GHRP approved anywhere — in Japan, as a diagnostic agent for GH deficiency — but it is not FDA-approved for treatment and is banned by WADA in sport. Store the dry vial cold and dark; once reconstituted, refrigerate and use within about 28 days.